Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Timolol for EGFR-TKI Induced Paronychia
NCT06140186Phase 3Recruiting
- Sponsor
- Queen Mary Hospital
- Start
- Apr 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of timolol maleate gel + placebo in paronychia (2 arms), sponsored by Queen Mary Hospital. Primary endpoint: Proportion of patients achieving complete response at 3 months. Started Apr 2023; status: recruiting.
02
Drugs
timolol maleate gel + placebo
03
Conditions
paronychia
Beyond the preview
Go deeper on NCT06140186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06140186.